| Launching a successful patient support programme (PSP) in Europe requires a thorough understanding of the European landscape. While orphan medications provide relief for patients’ symptoms, PSPs are beneficial in securing patients and their families a better quality of life. Investing in PSPs can also bring many advantages for biotechs and recognizing the challenges and strategies to effectively implement a PSP is vital to the ongoing success of the product. In our exclusive guide we explore: The benefits and advantages PSPs provide to biotechs Navigating the European regulatory environment and diverse healthcare systems Steps for successful PSP implementation Measuring the impact of a PSP Insight on partnership services to aid the successful launch of a PSP | 